srch

4 hours ago · Blueprint Medicines is co-developing another cancer drug, Gavreto (pralsetinib), with Roche RHHBY for treating patients with various types of RET-altered thyroid cancers and other solid tumors. In...

Company Description: Blueprint Medicines is a precision therapy company that identifies kinases that are drivers of genomically defined diseases and ...

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic ...

Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION annonce un chiffre d'affaires de .. 10/28: Blueprint Medicines Corporation fournit des prévisions de recettes pour l'ensemble de l.. 09/17: ROCHE: recommandation du CHMP pour Gavreto (pralsetinib) 09/08: CStone Pharmaceuticals affirme qu'un nouveau médicament se révèle efficace dans le ...

blueprint medicines corporation (nasdaq: bpmc), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on...

1 day ago · Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile,...

Blueprint Medicines Corporation develops and distributes biomedical treatments. The Company researches and produces medicines and treatments for cancer ...

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

1 dag siden · December. CAMBRIDGE, Mass., Dec. 30, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small ...

31.12.2021 · Shares of Blueprint Medicines Corporation BPMC have rallied 24.8% in the past six months against the industry’s decrease of 18.7%. Image Source: Zacks Investment Research The company has made steady progress with its lead drug, Ayvakit (avapritinib), approved by the FDA for the treatment of adult ...

30.12.2021 · CAMBRIDGE, Mass., Dec. 30, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of ...

Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on ...

4 timer siden · Shares of Blueprint Medicines Corporation BPMC have rallied 24.8% in the past six months against the industry’s decrease of 18.7%.. Image Source: Zacks Investment Research. The company has made ...

GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines’ collaboration with Roche.

Find the latest Blueprint Medicines Corporation (BPMC) stock quote, history, news and other vital information to help you with your stock trading and ...

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders.

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

Blueprint Medicines Appoints Daniella Beckman to its Board of Directors Dec 07, 2021 Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) More News Events and presentations Nov 29, 2021 Blueprint Medicines Conference Call Oct 28, 2021 Q3 2021 Blueprint Medicines Corp Conference Call More events and presentations

1 dag siden · Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a ...